Daclatasvir相关论文
1例62岁女性失代偿期丙型肝炎肝硬化患者接受索非布韦(400 mg口服，1次/d)和达卡他韦(60 mg口服，1次/d)治疗。服药18周后，患者出现双下......
,GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vi
NS3/4A serine protease is a prime target for direct-acting antiviral therapies against hepatitis C virus (HCV) infection......
,Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients
In order to develop an integrated pharmacokinetic/viral dynamic (PK/VD) model to predict long-term virological response ......
目的研究以达拉他韦（DCV）为基础直接抗病毒药物（DAAs）方案治疗中国慢性HCV感染者，评价其疗效及安全性。方法前瞻性、开放性、单中心、非......
泛基因型的全口服直接抗病毒药物是目前丙型肝炎治疗的发展趋势。临床试验和真实世界数据显示，达拉他韦联合索磷布韦方案可覆盖多种......
研究纳入64例慢性丙型肝炎病毒（HCV）感染者，均口服索磷布韦（SOF，400 mg）联合达拉他韦（DCV，60 mg）、1次/d，49例治疗12周，15例治疗24周。治疗后1......
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
Efficacy and safety of generic daclatasvir +sofosbuvir ± ribavirin in treatment of genotype 3infecte
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
目的观察应用索磷布韦/达拉他韦联合或不联合利巴韦林治疗慢性丙型肝炎(CHC)和丙型肝炎肝硬化(LC)患者的疗效和安全性。方法2016年......
Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently ava
AIM: To address the therapeutic efficacy of various treatment regimens in genotype 3 selecting randomized clinical trial......
AIM:Toevaluatedaclatasvirvstelaprevir,eachcombinedwithpeginterferonalfa-2a/ribavirin(pegIFN/RBV),intreatment-naivehepati......
Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C g
AIM To investigate the influence of interferon-free antivirus therapy on lipid profiles in chronic hepatitis C virus gen......
本文简要介绍了丙型肝炎的现状以及达卡他韦合成路线昀研究。为广大药学工作者了解新型抗丙型肝炎药达卡他韦提供了便利。本文通过......
AIM To survey the efficacy and safety of dual therapy with daclatasvir and asunaprevir in the elderly hepatitis C virus(......
Daclatasvir和asunaprevir作为直接抗病毒药物来联合治疗基因1b型慢性丙型肝炎患者,可获得较高的持续病毒学应答率。目前国内尚无......
Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C
The standard antiviral therapy for dialysis patients infected with hepatitis C virus(HCV)is(pegylated)interferon monothe......
Hepatitis C virus reinfection after liver transplant： New chances and new challenges in the era of d
The first interferon-free regimens have been approvedfor the treatment of patients with chronic hepatitisC virus （HCV）. In......
Daclatasvir plus asunaprevir in treatment-naive patients with hepatitis C virus genotype 1b infectio
AIM To assess daclatasvir plus asunaprevir(DUAL)in treatment-na?ve patients from mainland China,Russia and South Korea w......
Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination th
A 66-year-old,interferon-ineligible,treatment-naive man who was diagnosed with chronic hepatitis C due to hepatitis C vi......
Effects of dual sofosbuvir/daclatasvir therapy on,chronic hepatitis C infected,survivors of childhoo
BACKGROUND Childhood cancer survivors are potentially at a higher risk of infection with hepatitis C virus (HCV).The eff......
Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir:combined effects w
AIM To investigate the specific effects of immunosuppressants on the antiviral action of daclatasvir and asunaprevir.MET......
<正>【据《N Engl J Med》2014年1月报道】题:Daclatasvir联合sofosbuvir治疗初治或既往治疗过的慢性丙型肝炎(作者Sulkowski MS等......
